Metastasis remains one of the most clinically significant aspects of cancer progression, and there is ongoing interest in compounds that may interfere with tumor spread. Glinsky and Raz reviewed the anti-metastatic properties of modified citrus pectin (MCP), a soluble dietary fiber derivative obtained from citrus fruit that has been studied for its biological activity in cancer models.
This work summarizes preclinical evidence suggesting that MCP interacts with galectin-3, a carbohydrate-binding protein implicated in tumor cell adhesion, angiogenesis, immune evasion, and metastatic spread. By binding to galectin-3, MCP is proposed to interfere with multiple steps of the metastatic cascade, including cancer cell aggregation, endothelial adhesion, and establishment of secondary tumor sites.
Experimental studies described in this review show that MCP can reduce cancer cell adhesion to endothelial cells and may inhibit metastatic progression in animal models. These effects are thought to arise from disruption of galectin-3–mediated signaling pathways that contribute to tumor cell survival and dissemination.
Although the evidence is largely derived from in vitro and preclinical studies, the work highlights a biological mechanism through which this dietary-derived compound may influence metastatic behavior. These findings support further investigation into galectin-3 targeting strategies in cancer therapy.

Reference:

Glinsky VV, Raz A. Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. Carbohydr Res. 2009;344(14):1788–1791. doi:10.1016/j.carres.2008.08.038. PMID: 19061992; PMCID: PMC2782490.

The post Modified Citrus Pectin and Anti-Metastatic Activity appeared first on Integrated Health Clinic.

Mistletoe (Viscum album) preparations are widely used in some integrative oncology settings, primarily as supportive therapy aimed at improving tolerance to cancer treatment and overall well-being. Steele and colleagues conducted an observational study to evaluate the safety of intravenous mistletoe administration in patients with cancer.
In this study, oncology patients received intravenous mistletoe extracts in a clinical setting, and researchers systematically recorded adverse events, dosing patterns, and treatment tolerability. The focus was on assessing short- and medium-term safety outcomes rather than anti-cancer efficacy. Patients included a range of cancer types and disease stages, reflecting real-world use in integrative oncology practice.
The results indicated that intravenous mistletoe was generally well tolerated. Most reported adverse effects were mild to moderate and included transient flu-like symptoms such as fever, chills, fatigue, and local infusion-related reactions. Serious adverse events were rare and not consistently attributed to the mistletoe treatment. Overall, the safety profile was consistent with expected immunomodulatory effects.
Although this was an observational study without a control group and not designed to evaluate survival or tumor response, it provides real-world safety data supporting the tolerability of intravenous mistletoe preparations in oncology patients. These findings contribute to the evidence base informing its use as a complementary supportive therapy in cancer care.

Reference:

Steele ML, Axtner J, Happe A, Kröz M, Matthes H, Schad F. Safety of intravenous application of mistletoe (Viscum album L.) preparations in oncology: an observational study. Evid Based Complement Alternat Med. 2014;2014:236310. doi:10.1155/2014/236310. PMCID: PMC4052504.

The post Safety of Intravenous Mistletoe (Viscum album) in Oncology appeared first on Integrated Health Clinic.

Triple-negative breast cancer (TNBC) is an aggressive subtype with limited targeted treatment options, prompting interest in repurposing existing drugs such as metformin. Liu and colleagues investigated the biological and molecular effects of metformin on TNBC cells to better understand its potential anti-cancer mechanisms.
In this preclinical study, TNBC cell lines were treated with metformin, and researchers assessed changes in cell proliferation, cell cycle progression, and molecular signaling pathways. The study focused on identifying how metformin influences cancer cell metabolism and growth-related signaling at a cellular level.
The findings showed that metformin inhibited cell proliferation and induced cell cycle arrest in TNBC cells. These effects were associated with alterations in key signaling pathways involved in cellular metabolism and growth regulation, including activation of AMP-activated protein kinase (AMPK) and downstream inhibition of pathways that promote tumor growth. The study also highlighted changes in gene expression patterns, suggesting that metformin induces a distinct molecular response in TNBC cells.
Although this research was conducted in vitro and cannot be directly translated to clinical outcomes, it provides important mechanistic insight into how metformin may exert anti-cancer effects. These findings support further investigation into metformin as a potential adjunctive therapy in triple-negative breast cancer, particularly in strategies targeting cancer metabolism.

Reference:

Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 2009;8(13):2031–2040. doi:10.4161/cc.8.13.8814. PMID: 19440038.

The post Metformin and Molecular Effects in Triple-Negative Breast Cancer appeared first on Integrated Health Clinic.

Gastrointestinal toxicity, particularly diarrhea, is a common and often dose-limiting side effect of chemotherapy regimens such as FOLFOX in patients with colorectal cancer. Sabry and colleagues conducted a randomized controlled trial to evaluate whether supplementation with L-glutamine could reduce treatment-related toxicity and improve clinical outcomes.
In this study, patients with colon cancer receiving modified FOLFOX-6 chemotherapy were randomized to receive either L-glutamine supplementation or standard care. The primary outcomes included the incidence and severity of chemotherapy-induced diarrhea, while secondary outcomes assessed treatment response and overall survival.
The results demonstrated that patients receiving L-glutamine experienced a significant reduction in both the incidence and severity of diarrhea compared with the control group. In addition to improved tolerability, the intervention group showed better treatment response rates and a trend toward improved survival outcomes, suggesting that reducing toxicity may support more effective delivery of chemotherapy.
Although further studies are needed to confirm long-term survival benefits, this randomized trial provides clinically relevant evidence that glutamine-based supplementation may enhance treatment tolerance and potentially improve outcomes in patients undergoing chemotherapy for colorectal cancer.

Reference:

Sabry NM, Naguib TM, Kabel AM, Khafagy E-S, Arab HH, Almorsy WA. Ameliorative potential of L-alanyl L-glutamine dipeptide in colon cancer patients receiving modified FOLFOX-6 regarding the incidence of diarrhea, the treatment response, and patients’ survival: a randomized controlled trial. Medicina (Kaunas). 2022;58(3):394. doi:10.3390/medicina58030394.

The post L-Glutamine and Chemotherapy Tolerance in Colorectal Cancer appeared first on Integrated Health Clinic.

Immunotherapy has transformed cancer treatment, but many patients do not achieve durable responses. Magrì and colleagues investigated whether high-dose vitamin C could enhance the effectiveness of immunotherapy by modulating the tumor microenvironment and immune response.
This study used a combination of in vitro experiments and animal models of cancer to evaluate the effects of pharmacologic vitamin C in conjunction with immune checkpoint inhibitors. Researchers examined tumor growth, immune cell infiltration, and molecular changes within the tumor microenvironment when vitamin C was added to immunotherapy.
The results showed that high-dose vitamin C enhanced the anti-tumor activity of immunotherapy, leading to greater tumor regression compared with immunotherapy alone in preclinical models. This effect was associated with increased infiltration and activation of cytotoxic T cells within tumors, as well as epigenetic modulation that may improve tumor immunogenicity and immune recognition.
Although these findings are based on preclinical models, they provide strong mechanistic evidence that vitamin C may act as an immunomodulatory agent. This work supports further investigation into high-dose vitamin C as a potential adjunct to immunotherapy in cancer treatment.

Reference:

Magrì A, Germano G, Lorenzato A, Lamba S, Chilà R, Montone M, Amodio V, Ceruti T, Sassi F, Arena S, Abrignani S, D’Incalci M, Zucchetti M, Di Nicolantonio F, Bardelli A. High-dose vitamin C enhances cancer immunotherapy. Sci Transl Med. 2020;12(532):eaay8707. doi:10.1126/scitranslmed.aay8707. PMID: 32102933.

The post High-Dose Vitamin C Enhances Cancer Immunotherapy appeared first on Integrated Health Clinic.

Chronic inflammation is a common feature in cancer and is associated with disease progression, symptom burden, and reduced quality of life. Mikirova and colleagues investigated whether high-dose intravenous vitamin C could reduce markers of inflammation in patients with cancer.
In this observational study, cancer patients receiving high-dose intravenous vitamin C were monitored for changes in inflammatory biomarkers over time. Doses were typically in the pharmacologic range (often 15–50 g per infusion), administered intravenously at regular intervals. The primary outcomes included changes in C-reactive protein (CRP), as well as other inflammatory and tumor-related markers where available.
The study found that a significant proportion of patients experienced reductions in CRP levels following vitamin C treatment, particularly those who had elevated baseline inflammation. Decreases in other markers associated with inflammation and tumor activity were also observed in some patients. These findings suggest that high-dose intravenous vitamin C may exert anti-inflammatory effects in the context of cancer, potentially through modulation of inflammatory signaling pathways.
Although this was not a randomized controlled trial and lacked a comparison group, the results reinforce the role of intravenous vitamin C as a clinically relevant supportive therapy in oncology, with anti-inflammatory effects that may contribute to improvements in symptom burden, quality of life, and overall treatment tolerance.

Reference:

Mikirova N, Casciari J, Rogers A, Taylor P. Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J Transl Med. 2012;10:189. doi:10.1186/1479-5876-10-189. PMID: 22963460; PMCID: PMC3480897.

The post High-Dose Intravenous Vitamin C and Inflammation in Cancer Patients appeared first on Integrated Health Clinic.

Metabolic health, particularly blood glucose regulation, has been increasingly linked to cancer risk. Crawley and colleagues conducted a meta-analysis to evaluate the association between serum glucose levels and the risk of developing cancer across multiple populations and study designs.
This analysis pooled data from numerous prospective cohort studies examining fasting blood glucose levels and subsequent cancer incidence. Participants were grouped based on glucose levels, including normal, impaired, and elevated ranges, and outcomes included the development of various cancers such as colorectal, breast, and pancreatic cancer. The large sample size allowed for more robust estimates of risk across different populations.
The findings demonstrated that higher serum glucose levels were associated with an increased risk of developing cancer, even within ranges not classified as overt diabetes. The association appeared dose-dependent, with progressively higher glucose levels correlating with greater cancer risk. This relationship is thought to be mediated through mechanisms such as insulin resistance, chronic inflammation, and increased availability of glucose to fuel tumor growth.
While observational in nature and unable to establish causation, this meta-analysis highlights the importance of metabolic health in cancer prevention. Maintaining healthy blood glucose levels through diet, physical activity, and overall lifestyle may play a role in reducing cancer risk, supporting a broader integrative approach to long-term health.

Reference:

Crawley DJ, Holmberg L, Melvin JC, Loda M, Chowdhury S, Rudman SM, Van Hemelrijck M. Serum glucose and risk of cancer: a meta-analysis. BMC Cancer. 2014;14:985. doi:10.1186/1471-2407-14-985. PMID: 25526881; PMCID: PMC4320469.

The post Serum Glucose and Cancer Risk: A Meta-Analysis appeared first on Integrated Health Clinic.

Pancreatic cancer is often treated with radiation therapy, but effectiveness can be limited by both tumor resistance and damage to surrounding healthy tissues. Alexander and colleagues investigated whether high-dose intravenous vitamin C (pharmacologic ascorbate) could simultaneously enhance tumor sensitivity to radiation while protecting normal tissues.
This study combined laboratory experiments with animal models of pancreatic cancer to evaluate the effects of pharmacologic ascorbate given alongside radiation therapy. High concentrations of vitamin C were administered to achieve pro-oxidant effects, generating hydrogen peroxide selectively in tumor tissues. Researchers assessed tumor response, oxidative stress markers, and indicators of normal tissue toxicity following radiation exposure.
The findings showed that pharmacologic ascorbate enhanced the cytotoxic effects of radiation in pancreatic tumor cells, leading to increased tumor cell death and improved tumor control in preclinical models. At the same time, vitamin C appeared to reduce radiation-induced damage in normal tissues, suggesting a dual effect of tumor radiosensitization and normal tissue protection.
Although these results are based on preclinical models, they provide strong mechanistic support for the use of high-dose intravenous vitamin C as an adjunct to radiation therapy. The study highlights a promising therapeutic strategy that may improve treatment effectiveness while reducing side effects, supporting further investigation in clinical trials involving patients with pancreatic cancer.

Reference:

Alexander MS, Wilkes JG, Schroeder SR, Buettner GR, Wagner BA, Du J, Gibson-Corley K, O’Leary BR, Spitz DR, Buatti JM, Berg DJ, Bodeker KL, Vollstedt S, Brown HA, Allen BG, Cullen JJ. Pharmacologic ascorbate reduces radiation-induced normal tissue toxicity and enhances tumor radiosensitization in pancreatic cancer. Cancer Res. 2018;78(24):6838–6851. doi:10.1158/0008-5472.CAN-18-1680. PMID: 30254147; PMCID: PMC6295907.

The post Pharmacologic Vitamin C Enhances Radiation Response in Pancreatic Cancer appeared first on Integrated Health Clinic.

Hot flashes are a frequent and often debilitating side effect of androgen deprivation therapy in men with prostate cancer, with limited well-tolerated treatment options. Beer and colleagues evaluated the feasibility and effectiveness of acupuncture in reducing hot flash symptoms in this population.
In this prospective clinical study, men with prostate cancer experiencing bothersome hot flashes underwent a standardized acupuncture protocol, typically consisting of biweekly treatments over a 4-week period followed by weekly sessions for an additional 6 weeks. Outcomes assessed included hot flash frequency and severity, often measured using patient-reported diaries and composite hot flash scores, as well as quality of life indicators.
The study found a clinically meaningful reduction in hot flash frequency and composite scores over the course of treatment, with some patients experiencing improvements of approximately 50% or greater. Symptom relief often began within the first few weeks and was sustained for several months following completion of acupuncture therapy. Treatment was well tolerated, with minimal adverse effects reported.
While the study was not a large randomized controlled trial, these findings suggest that acupuncture may provide a safe and effective non-pharmacologic option for managing androgen deprivation–related hot flashes in prostate cancer patients. The durability of response and favorable tolerability profile support further investigation in larger controlled studies.

Reference:

Beer TM, Benavides M, Emmons SL, Hayes M, Liu G, Garzotto M, Donovan D, Katovic N, Reeder C, Eilers K. Acupuncture for hot flashes in patients with prostate cancer. Urology. 2010;76(5):1182–1188. doi:10.1016/j.urology.2010.03.033. PMID: 20494414.

The post Acupuncture for Hot Flashes in Prostate Cancer Patients appeared first on Integrated Health Clinic.

Supportive therapies that reduce treatment-related side effects and improve quality of life are an important focus in breast cancer care. Vollbracht and colleagues evaluated the impact of intravenous vitamin C on symptom burden and overall well-being in patients undergoing chemotherapy, radiotherapy, and follow-up care.
This retrospective, multicentre cohort study in Germany included several hundred breast cancer patients who received standard oncologic therapy, with a subset also receiving adjunctive intravenous vitamin C. The vitamin C group received repeated infusions (commonly 7.5 g per infusion) administered one to three times per week during active treatment and, in some cases, continued into the aftercare phase. Outcomes were assessed using physician-documented and patient-reported measures of common therapy-related symptoms, including fatigue, nausea, depression, sleep disturbances, and functional impairment.
The investigators reported that patients receiving intravenous vitamin C experienced statistically significant reductions in several key symptoms compared with the control group. Improvements were particularly notable in fatigue, nausea, appetite loss, sleep disorders, and overall performance status. These benefits were observed both during chemotherapy and radiotherapy and persisted into the post-treatment period. The treatment was well tolerated, with no serious adverse effects attributed to vitamin C administration reported in the cohort.
Although the retrospective design limits causal interpretation and introduces the possibility of selection bias, the consistency of symptom improvement across multiple domains supports the use of adjunctive intravenous vitamin C in breast cancer care. These findings support further investigation through prospective randomized trials to better define efficacy, optimal dosing, and patient selection.

Reference:

Vollbracht C, Schneider B, Leendert V, Weiss G, Auerbach L, Beuth J. Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo. 2011;25(6):983–990. PMID: 22021693.

The post Intravenous Vitamin C and Quality of Life in Breast Cancer Patients appeared first on Integrated Health Clinic.